Background: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD).
Methods: We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores.
Results: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy.
Discussion: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations.
Highlights: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.12790 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrasensitive Protein Aggregate Quantification Assays for Neurodegenerative Diseases on the Simoa Platform.
Anal Chem
December 2024
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
Nanoscale aggregates play a key role in the pathogenesis of neurodegenerative disorders such as Alzheimer's and Parkinson's disease. However, quantifying these aggregates in complex biological samples, such as biofluids and postmortem brain tissue, has been challenging due to their low concentration and small size, necessitating the development of methods with high sensitivity and specificity. Here, we have developed ultrasensitive assays utilizing the Quanterix Simoa platform to detect α-synuclein, β-amyloid and tau aggregates, including those with common posttranslational modifications such as truncation of α-synuclein and AT8 phosphorylation of tau aggregates.
View Article and Find Full Text PDFPrognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation.
Eur J Neurol
January 2025
Department of Neurology, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.
Background: We aimed to investigate the prognostic role of β-synuclein in comparison to that of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for predicting functional outcome after acute ischemic stroke (AIS).
Methods: We measured serum concentrations of β-synuclein, NfL and GFAP 24 h after hospital admission in 213 consecutive patients with moderate-to-severe AIS. We investigated the association between serum biomarkers and radiological/clinical characteristics, 3-months mortality and functional outcome on the modified Rankin Scale (mRS).
Dimethyl labeling of N-terminal amines allows unambiguous identification of protein crosslinks.
Free Radic Biol Med
December 2024
Dept. of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address:
Article Synopsis
- Protein crosslinks caused by oxidative stress are linked to diseases like atherosclerosis, Alzheimer's, and Parkinson's, but their specific nature and locations in proteins remain unclear.
- A new method utilizing "light" and "heavy" isotope-labeled reagents for efficient amine labeling of crosslinked peptides has shown improved identification and quantification over previous techniques.
- This approach has led to the successful identification of novel crosslinks in proteins like β-casein and α-synuclein, as well as effective mapping of disulfide bonds in serum albumin, highlighting its versatility for studying protein modifications.
Cognitive impairment in Parkinson's disease and other parkinsonian syndromes.
J Neural Transm (Vienna)
November 2024
Department of Neurology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Stavrou Niarchou Av., University Campus, Ioannina, Greece.
Article Synopsis
- This review discusses mild cognitive impairment in Parkinson's disease and atypical parkinsonian disorders, emphasizing the overlap in symptoms and recent diagnostic criteria.
- It highlights how conditions like progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy can also lead to significant cognitive decline.
- The use of biomarkers such as MRI, FDG-PET, and specific proteins is becoming crucial for early diagnosis and differentiating these disorders, indicating a need for ongoing research to improve diagnostic methods and treatment options.
FBXL16: a new regulator of neuroinflammation and cognition in Alzheimer's disease through the ubiquitination-dependent degradation of amyloid precursor protein.
Biomark Res
November 2024
Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau S.A.R, Avenida Wai Long, Macau, 999078, China.
Background: Activating the ubiquitin-proteasome system to dismantle disease- related proteins such as tau, β-amyloid, APP, and α-synuclein is an important focus in the research of neurodegenerative proteinopathy. By analyzing the serum RNA extracted from wild-type and Alzheimer's disease (AD) transgenic mice at different ages (4, 8, and 12 months), this study revealed a new protective role of FBXL16 in AD, primarily through facilitating the degradation of disease-related proteins via the ubiquitin proteasome system.
Methods: Proteomic analysis were conducted using protein lysates from HEK293 cells overexpressing FBXL16 to identify potential interacting proteins that interact with FBXL16.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!